Claims for Patent: 9,470,687

Summary for Patent: 9,470,687

Title:	SRM/MRM assay for subtyping lung histology
Abstract:	The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins that are particularly advantageous for quantifying the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from said biological sample using the Liquid Tissue.TM. reagents and protocol and the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins are quantitated in the Liquid Tissue.TM. sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of a KRT5, KRT7, NapsinA, TTF1, TP63, and MUC1 fragment peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.
Inventor(s):	Krizman; David B. (Gaithersburg, MD), Liao; Wei-Li (Herndon, VA), Thyparambil; Sheeno (Frederick, MD), Hembrough; Todd (Gaithersburg, MD)
Assignee:	Expression Pathology, Inc. (Rockville, MD)
Application Number:	14/935,586
Patent Claims:	1. A method for determining whether the cancer in a patient suffering from non-small cell lung cancer is adenocarcinoma or squamous cell carcinoma comprising measuring the level of the KRT5, KRT7, Napsin A, TTF1, TP63, and MUC1 proteins in a human biological sample of formalin-fixed tumor tissue from said patient, comprising detecting and quantifying the amount of a KRT5 fragment peptide, a KRT7 fragment peptide, a Napsin A fragment peptide, a TTF1 fragment peptide, a TP63 fragment peptide, and a MUC1 protein fragment peptide in a protein digest prepared from said biological sample, using mass spectrometry; and calculating the level of KRT5, KRT7, Napsin A, TTF1, TP63, and MUC1 protein in said sample; wherein the Napsin A fragment peptide is the peptide of SEQ ID NO:5 and MUC1 peptide is the peptide of SEQ ID NO:6, wherein said amount is a relative amount or an absolute amount, and whereby when one, two, three or four of said KRT7, MUC1, TTF1, and Napsin A fragment peptides are detected and one or both of said KRT5 and TP63 fragment peptides are not detected is indicative of adenocarcinoma and whereby when one or both of KRT5 and TP63 proteins are detected and KRT7, MUC1, TTF1, and Napsin A are not detected is indicative of squamous cell carcinoma. 2. The method of claim 1, further comprising the step of fractionating said protein digest prior to detecting and quantifying the amount of said KRT5, KRT7, NapsinA, TTF1, TP63, and MUC1 protein fragment peptides. 3. The method of claim 1, wherein said protein digest comprises a protease digest. 4. The method of claim 1, wherein quantifying the KRT5, KRT7, Napsin A, TTF1, TP63, and MUC1 protein fragment peptides comprises comparing an amount of one or more KRT5, KRT7, Napsin A, TTF1, TP63, and MUC1 fragment peptides in one biological sample to the amount of the same KRT5, KRT7, Napsin A, TTF1, TP63, and MUC1 fragment peptides in a different and separate biological sample. 5. The method of claim 1, wherein quantifying the KRT5, KRT7, Napsin A, TTF1, TP63, and MUC1 fragment peptides comprises determining the amount of the each of the KRT5, KRT7, NapsinA, TTF1, TP63, and MUC1 fragment peptides in a biological sample by comparison to an added internal standard peptide of known amount, wherein each of the KRT5, KRT7, Napsin A, TTF1, TP63, and MUC1 fragment peptides in the biological sample is compared to an internal standard peptide having the same amino acid sequence. 6. The method of claim 5, wherein the internal standard peptide is an isotopically labeled peptide. 7. The method of claim 1, further comprising correlating the results of said detecting and quantifying the amount of the KRT5, KRT7, Napsin A, TTF1, TP63, and MUC1 fragment peptides, or the amount of said KRT5, KRT7, Napsin A, TTF1, TP63, and MUC1 proteins to the diagnostic stage/grade/status of the cancer. 8. The method of claim 7, wherein correlating the results of said detecting and quantifying the amount of the KRT5, KRT7, Napsin A, TTF1, TP63 and MUCI fragment peptides, or the amount of said KRT5, KRT7, Napsin A, TTF1, and TP63 and MUC1 proteins to the diagnostic stage/grade/status of the cancer is combined with detecting and/or quantifying the amount of other proteins or peptides from other proteins in a multiplex format to provide additional information about the diagnostic stage/grade/status of the cancer. 9. The method of claim 1, further comprising administering to said patient a therapeutically effective amount of a therapeutic agent, wherein the therapeutic agent and/or amount of the therapeutic agent administered is based upon whether said patient is determined to be suffering from adenocarcinoma or squamous cell carcinoma. 10. The method of claim 9, wherein said therapeutic is selected from pemetrexed and bevacizumab when said patient is determined to be suffering from adenocarcinoma. 11. The method according to claim 1 wherein the KRT5 fragment peptide is the peptide of SEQ ID NO:2, the KRT7 peptide is the peptide of SEQ ID NO:3, the TTF1 peptide is the peptide of SEQ ID NO:8 and the TP63 peptide is the peptide of SEQ ID NO: 11. 12. The method of claim 1, wherein the tissue is paraffin-embedded tissue.

Details for Patent 9,470,687

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-05-15